Premature senescence is considered as a cellular defense mechanism to prevent tumorigenesis. Although recent evidences show that c-Jun N-terminal kinase (JNK) is involved in the senescence process, the mechanism for this regulation is not fully understood. Here, we examined the role of JNK in premature senescence of tumor cells. Treatment of cells with the JNK-specific inhibitor SP600125 caused phenotypical changes of senescence and triggered a rapid increase in mitochondrial reactive oxygen species (ROS) production and DNA-damage response (DDR) in MCF7 breast carcinoma cells. ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Bax did not change their localization to the mitochondria, which is required for apoptosis. The essential roles of JNK and phosphorylated Bcl-2 in preventing premature senescence were confirmed using RNA interference and ectopic expression of mutants of Bcl-2, including phosphomimetic and nonphosphorylatable forms. These findings were evidenced in H460 lung carcinoma cells and primary human embryonic fibroblasts. Altogether, our results showed that loss of JNK activity triggers a Bcl-2/ROS/DDR signaling cascade that ultimately leads to premature senescence, indicating that basal JNK activity is essential in preventing premature senescence.
Introduction
Premature senescence occurs when normal human somatic cells irreversibly lose their self-renewal capability after completing a limited number of cell divisions (Hayflick and Moorhead, 1961) . Senescent cells undergo functional and morphological changes, including senescence-associated b-galactosidase (SA-bGal) activity (Goletz et al., 1994; Dimri et al., 1995) . Tumor-derived cell lines are generally capable of limitless proliferation. Indeed, the ability to repress senescence pathways seems to contribute to such a limitless replicative potential in tumorigenesis (Roninson, 2003) . Previous reports have shown that the expression of critical regulators can reactivate the genetic program of senescence, resulting in loss of immortality (Roninson, 2002; Sharpless, 2004) . In agreement with a role of senescence in tumor prevention, senescence could be an efficient brake on tumor progression.
The mitogen-activated protein kinases (MAPKs) are components of intracellular signal transduction pathways whose activation influences a variety of cellular activities. MAPKs can promote differentiation, cell survival, growth arrest, apoptosis, senescence, and resistance to radiotherapy and chemotherapy (Marchetti et al., 2005) . The three distinct MAPK signaling cascades lead to activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) or p38 (Raman et al., 2007; Turjanski et al., 2007) . Although the ERK pathway is often activated by mitogenic stimuli, p38 can be stimulated by various stresses. The JNK pathway is involved in stress-related responses and mediates apoptotic cell death (Park et al., 2001) . The role of this MAPK in increasing activating protein-1 (AP-1)-dependent gene expression suggests that JNK may have an important role in cellular responses to mitogens (Shaulian and Karin, 2002) . Furthermore, primary murine fibroblasts isolated from Jnk1 À/À Jnk2 À/À embryos proliferate slowly (Tournier et al., 2000) . Embryonic fibroblasts of mkk7 À/À also show impaired proliferation and premature senescence (Wada et al., 2004) . Altogether, these observations suggest that JNK may function to regulate cell cycle progression (Das et al., 2007) . However, the target and exact mechanism of JNK signaling in the regulation of cell proliferation has yet to be defined.
The B-cell lymphoma-2 (Bcl-2) family of proteins is a key determinant of cell survival and is essential for normal development and organ homeostasis (Kerr et al., 2007) . Bcl-2 family proteins are divided into three subgroups: anti-apoptotic, pro-apoptotic and Bcl-2 homology-3-only family members (Huang and Cidlowski, 2002) . Selective binding between anti-apoptotic and proapoptotic Bcl-2 family members regulates apoptosis by affecting the permeability of the mitochondrial membrane (Deng et al., 2006) . The anti-apoptotic role of Bcl-2 in response to various stresses has also been observed in many cellular systems. Recently, a link between Bcl-2 phosphorylation and cell cycle retardation has been proposed (Deng et al., 2003 (Deng et al., , 2004 ; however, this exact mechanism remains uncharacterized.
In this study, we investigated which MAPK has a critical role in maintaining cell cycle progression and in preventing triggering of premature senescence. We showed that JNK basal activity is indispensable for cell cycle progression. Loss of JNK activity induces permanent cell cycle arrest following inhibition of Bcl-2 phosphorylation, generation of reactive oxygen species (ROS) in the mitochondria and induction of the DNAdamage response (DDR).
Results
Basal JNK activity is essential in preventing premature senescence To examine the role of MAPKs in premature senescence, we assessed senescence-related phenotypes in MCF7 breast carcinoma cells treated with MAPK inhibitors. Cells treated with the JNK inhibitor, SP600125, showed senescence-specific large and flat cellular morphology and stained positively for SA-bGal activity (Figure 1a) . Such senescence-related changes were observed in dose-and time-dependent manners in SP600125-treated cells, but not in cells treated with the ERK inhibitor, PD98059, or the p38 inhibitor, SB203580 (Figure 1b and Supplementary  Figure 1) . Positive SA-b-Gal activity gradually increased up to 7 days after SP600125 treatment (Figure 1c ). Analysis of cell cycle distribution revealed that only SP600125-treated cells were arrested in the G2/M phase and that the number of aneuploid cells (>4N) also increased ( Figure 1d ). In addition, only SP600125 treatment reduced cell number (Figure 1e ). To check the possibility that such a decrease in cell number is due to induction of apoptosis, we compared cellular morphology, PARP cleavage and trypan blue exclusion with those of taxol (paclitaxel)-treated cells as a positive control for apoptosis (Supplementary Figure 2) . These results indicated that the JNK inhibitor principally activated the premature senescence pathway, not apoptosis. When the cell cycle regulatory proteins were examined in SP600125-treated cells, an increase in p53 was observed immediately after treatment and was maintained throughout premature senescence ( Figure 1f ). Expression of p21 was increased within several hours and was maintained, and phosphopRB was dramatically reduced. In addition, inactive phospho-Cdc25C increased, and the levels of cyclin B and cyclin-dependent kinase 2 (CDK2) decreased. Inhibition of JNK activity by SP600125 was confirmed by the loss of phospho-c-Jun. Collectively, these results suggest that both the p53/p21/pRB and CHK2/Cdc25C/cyclin B-Cdc2 signaling pathways were activated to inhibit cell cycle progression following JNK inhibition.
Increased ROS production triggers the DDR in JNK inhibitor-induced premature senescence Reactive oxygen species have been implicated in regulating many important cellular events, including premature senescence (Macip et al., 2003) . Thus, to address this in JNK inhibitor-induced premature senescence, ROS levels were examined. Only SP600125-treated cells showed dose-and time-dependent increases in ROS levels (Figures 2a and b) . The decrease in intracellular ROS levels observed 3 days after treatment may be due to an upregulation in the antioxidant proteins, Cu/ZnSOD, MnSOD, and catalase ( Figure 3b ). Mitochondria are the major source of intracellular ROS, which are generated as by-products of cellular respiration (Balaban et al., 2005) . To examine the involvement of mitochondria in the JNK inhibitorinduced premature senescence pathway, we measured fluorescence of MitoSOX Red, a mitochondrial superoxide indicator, and observed that fluorescence intensity increased 30 min after SP600125 treatment (Figure 2c) , which was consistent with ROS production (Figure 2b ). To further confirm the mitochondrial origin of ROS, when cells were incubated with rotenone and potassium cyanide, inhibitors of the mitochondrial respiratory Role of JNK in premature senescence J-J Lee et al chain, before SP600125 treatment, the increase in ROS production was abolished ( Figure 2d ).
As ROS production can trigger DDR, we next investigated whether JNK inhibition leads to DNA damage using a standard comet assay. The SP600125-treated cells exhibited distinctive comet tails, indicating DNA strand breaks, 30 min after inhibitor treatment, and nearly all cells were positive for DDR by 24 h (Figure 2e ). In contrast, when cells were pretreated with the ROS scavenger N-acetyl-L-cysteine (NAC), cometpositive cells were barely detectable after 30 min, and the number of comet-positive cells evidently decreased by 24 h after treatment with SP600125. Senescence-associated ROS production and morphological changes were also abrogated by the pretreatment of NAC (Figure 2f ).
Inhibition of basal JNK activity generates ROS through suppression of Bcl-2 phosphorylation As the mitochondria-generated ROS seem to have a key role in JNK inhibitor-induced premature senescence through DDR, the biochemical state of Bcl-2 was subsequently examined. Bcl-2 is a substrate of JNK and is essential for the maintenance of mitochondrial integrity (Deng et al., 2001; Tomita et al., 2006) . When levels of total Bcl-2 were assessed, the Bcl-2 level was increased (Figures 3a and b) . However, in the presence of SP600125, Bcl-2 phosphorylation began to decrease after 30 min and it was barely detectable after 24 h. Accumulation of p53 was observed at 30 min and 24 h after SP600125 treatment (Figure 3a) . To examine the role of ROS in the status of Bcl-2 phosphorylation and p53 accumulation, cells were incubated with NAC before SP600125 treatment. Although the decrease in phosphorylated Bcl-2 remained unaffected, the increase in p53 was inhibited with NAC treatment after 30 min and 24 h (Figure 3a) , suggesting that ROS accumulation is downstream of Bcl-2 dephosphorylation but upstream of p53 accumulation in the signaling cascade.
Intracellular ROS levels are tightly regulated by the enzymatic antioxidant defense system that serves to protect cells against oxidative damage (Mates and Sanchez-Jimenez, 1999) . During senescence, a significant upregulation of antioxidant enzymes, such as Mn SOD, Cu/Zn SOD, and catalase was observed, and even a transient decrease of MnSOD was detected during the first 3 days after SP600125 treatment ( Figure 3b ). This increase correlated closely with changes in ROS and mitochondrial superoxide levels as shown in Figure 2 . Under pro-apoptotic conditions, Bax and p53 undergo conformational changes and translocate to the mitochondria from the cytosol (Nechushtan et al., 1999) . When subcellular localizations of Bax and p53 were investigated, we found that Bax localization was not altered during SP600125-induced senescence ( Figure 3c ). However, a small portion of p53 translocated to the mitochondria. Next, we examined the role of p53 in premature senescence using p53-specific inhibitor (pifithrin-a) or small interfering RNA (siRNA) against p53. When p53 was inhibited, induction of p21 and premature senescence were prevented (Figure 3d ).
Loss of either JNK or Bcl-2 induces premature senescence
To confirm whether the loss of JNK and Bcl-2 directly triggers premature senescence, experiments using siRNAs directed against either signaling molecule were conducted. As shown in Figure 4a , siRNA transfection specifically diminished the levels of JNK and Bcl-2. Phosphorylated Bcl-2 was no longer detectable in cells transfected with siRNAs against JNK, indicating that basal Bcl-2 phosphorylation is exclusively maintained by JNK. Cells transfected with either siRNA directed against JNK or Bcl-2 exhibited senescence-like morphological changes and SA-b-Gal activity (Figure 4b ). Further evidence that JNK and Bcl-2 siRNA transfection resulted in cell cycle arrest included an observed decrease in cell number and lack of detectable phosphorylated pRb (Figures 4a and c) . Both siRNA transfectants showed p53 and p21 accumulation and did not exhibit apoptotic indicators, such as PARP cleavage and positivity of propidium iodide staining ( Figure 4d ). As PKC-a and CDK1 are also known as upstream kinases of Bcl-2 (Ruvolo et al., 1998; Furukawa et al., 2000) , we tested whether PKC-a and CDK1 could involve in premature senescence. The PKC-a inhibitor (GÖ 6976) and CDK1 inhibitor (CGP74514A) did not elicit premature senescence phenotype (Supplementary Figure 3) .
As JNK seems to be involved in the phosphorylation of Thr69, Ser70 and Ser87 on Bcl-2 (Deng et al., 2006), (a) Status of p53 and Bcl-2 in SP600125-treated cells in the presence or absence of N-acetyl-L-cysteine (NAC). Cell lysates were prepared before western blotting using antibodies specific to total and phosphorylated Bcl-2, p53 and actin. SE, short exposure; LE, long exposure. (b) Western blot analysis of whole-cell lysates. Lysates were prepared from cells treated with SP600125 for the indicated times and then subjected to western blotting using antibodies specific to the indicated proteins. (c) Western blot analysis of mitochondrial (Mito) and cytosolic (Cyto) fractions. Each fraction was prepared from cells treated with SP600125 for the indicated times and then subjected to western blotting using antibodies specific to the indicated proteins. Bcl-2 and a-tubulin were probed as mitochondrial and cytosolic fraction markers, respectively. SE, short exposure; LE, long exposure. (d) Senescence-associated b-galactosidase activity and western blot analysis after pifithrin-a treatment (upper panel) or p53 small interfering RNA (siRNA) treatment (lower panel). Cells were treated with SP600125 in the presence or absence of pifithrin-a or p53 siRNA.
we ectopically expressed wild-type (Bcl-2 WT) and mutant forms of Bcl-2, including a phosphomimetic form, T69E/S70E/S87E (Bcl-2 EEE), and nonphosphorylatable form, T69A/S70A/S87A (Bcl-2 AAA). Bcl-2 AAA resulted in a senescence-like flat, enlarged cell morphology 7 days after transfection (Figure 5a ) and reduced cell proliferation and colony-forming ability (Figure 5b ). In addition, an increase in cellular ROS levels was seen only in these cells (Figure 5c ). In contrast, Bcl-2 WT-and Bcl-2 EEE-expressing cells, as well as cells expressing an empty vector, did not show any senescence-related phenotypes or increases in ROS levels. When SP600125 was treated in Bcl-2 EEEexpressing cells, levels of ROS, p53 and p21were not altered and senescence phenotypes were not observed (Figure 5d ). These results confirm that loss of basal JNK activity triggers premature senescence by preventing Bcl-2 phosphorylation. Together with the data presented above, these results show that mitochondrial ROS generation by JNK inactivation and Bcl-2 dephosphorylation could engage premature senescence through DDR.
JNK/Bcl-2/ROS/DNA damage signaling pathway mediates premature senescence in lung carcinoma cells and HEFs We wanted to know whether JNK inhibition influenced premature senescence in other carcinoma cell types. When H460 lung carcinoma cells were treated with SP600125, cellular morphology, SA-b-Gal activity and colony-formation ability were compatible with senescence, indicating that this biological process was induced (Figure 6a ). Loss of phospho-Bcl-2 and phospho-pRB was also detected (Figure 6b ). Furthermore, ROS generation and DDR were observed (Figures 6c and d) along with a decrease in S-phase entry ( Figure 6e) .
Next, we determined that basal JNK activity is also critical in preventing premature senescence in primary cultured cells. When primary human embryonic fibroblasts (HEFs) were treated with SP600125, the cells showed senescence morphology with SA-b-Gal activity (Figure 7a ) and loss of phospho-Bcl-2 and phosphopRB (Figure 7b ). The JNK inhibitor induced ROS generation and DNA damage, and finally resulted in a decrease in cell number (Figures 7c-e) . HEFs transfected with siRNA of JNK or Bcl-2 exhibited SA-b-Gal activity and decreased cell numbers (Figures 7f and g ). These data confirm that JNK inhibition can also induce premature senescence through a JNK/Bcl-2/ROS/DDR pathway in both tumor cells and normal cells.
JNK inhibition sensitizes tumor cells to premature senescence in response to ionizing radiation Recently, premature senescence has begun to be considered a promising tumor treatment (Campisi, 2005) . Ionizing radiation (IR) has been shown to trigger premature senescence in solid tumors (Jones et al., 2005) . Therefore, we examined whether premature senescence in tumor cells can be accelerated through combined exposure to IR and SP600125. MCF7 cells were exposed to 2-20 mM SP600125 alone, a 2-6 Gy dose of IR alone or combinations of both. As expected, exposure of MCF7 cells to both SP600125 and IR increased the induction of premature senescence (Figure 8a ). Even the defect or low effect of 2 or 4 Gy IR exposure alone was significantly enhanced by the addition of 5 or 10 mM SP600125, as evidenced by SA-b-Gal activity and colony formation (Figures 8a  and b) . Therefore, combined SP600125 and IR treatment could enhance radiotherapy efficacy in tumor cells.
Discussion
Previous studies using RNA interference and the JNK inhibitor, SP600125, have suggested a role for JNK in the G2 phase of the cell cycle (Du et al., 2004; Wada et al., 2004) . However, the underlying mechanism remained unresolved. Recent evidence indicates that the anti-apoptotic functions of Bcl-2 can be regulated by post-translational modifications (Huang and Cidlowski, 2002) . Reports have implicated JNK as the kinase responsible for phosphorylating the Thr69, Ser70 and Ser87 residues on Bcl-2 (Yamamoto et al., 1999) . In addition, mutations that prevent phosphorylation of these residues have been shown to enhance antiapoptotic activity (Haldar et al., 1995; Muller et al., 2005) . However, other groups have reported that Ser70 phosphorylation may be required for its full, potent anti-apoptotic function (Deng et al., 2004 (Deng et al., , 2006 Du et al., 2005) . Although increasing evidence suggests that apoptosis is dependent on Bcl-2 phosphorylation, controversy still exists. In addition, little is known about how Bcl-2 phosphorylation actually affects premature senescence. In this study, we showed the essential roles of JNK and Bcl-2 in preventing premature senescence. Premature senescence induced by inhibition of basal JNK activity was mediated by repression of Bcl-2 phosphorylation. Loss of either JNK activity or Bcl-2 phosphorylation triggered ROS generation and the DDR signaling cascade, ultimately leading to permanent cell cycle arrest. Reactive oxygen species have recently been implicated in the regulation of many important cellular events . Senescent cells have higher levels of ROS than normal cells (Hagen et al., 1997) , and both oncogenic Ras and CDK inhibitor p21 induce premature senescence in association with increased intracellular ROS (Macip et al., 2002) . Excessive ROS production activates events that lead to cell death, and mitochondria could be a major source of ROS production . To minimize the potential toxic effects of ROS, aerobic organisms have evolved enzymatic antioxidant defense systems, including SOD, GPx, Prx and catalase (Chan et al., 2006) . Bcl-2 prevents the opening of the mitochondrial permeability transition pore complex (PTPC), which results in disruption of the inner mitochondrial transmembrane potential (Susin et al., 1997) . ROS are formed as a result of the uncoupling of the respiratory chain due to PTPC opening (Zamzami et al., 1998) . The phosphorylation status of Bcl-2 influences its ability to prevent ROS generation and promote survival (Deng et al., 2003) . It is also possible that Bcl-2 acts as an antioxidant in a mechanism involving the regulation of antioxidant enzyme expression (Zimmermann et al., 2007) . At these two levels, Bcl-2 could have a central role as an antioxidant.
In this study, we confirmed that ROS accumulation was derived from the mitochondria and that attenuation of the mitochondrial membrane potential was an immediate, early response to JNK inhibition. The DDR network, including DNA-damage sensing and signaling pathways, is closely related to the intracellular ROS level and regulates cell proliferation, cell cycle arrest, premature senescence and apoptosis (Schmitt et al., 2007) . Our data showed that DNA damage observed 30 min after SP600125 treatment was abrogated by treatment with the ROS scavenger NAC, suggesting that DDR activated by ROS accumulation has a critical role in inducing premature senescence following JNK inhibition. We also found a significant upregulation of antioxidants, including SOD and catalase proteins, and this upregulated expression was closely related to the decrease in intracellular ROS levels during the later period of JNK inhibitor-induced premature senescence. We propose that, to protect senescent cells against cell death, this increase in antioxidants may work to reinstate the appropriate ROS levels following an early burst in response to an initial signal.
Some groups have shown that defects in cell proliferation are not due to apoptosis but due to senescence (Bihani et al., 2007) . Inhibition of the JNK pathway through MKK7/4 À/À induces a G2/M cell cycle block and premature senescence (Wada et al., 2004) . Mouse embryonic fibroblasts obtained from JNK1 and JNK2 double-knockout embryos proliferate slowly. In addition, inhibition of JNK activity by the treatment of SP600125 resulted in G2/M arrest and apoptosis (Du et al., 2004) . Some reports suggest that Bcl-2 overexpression contributes to cell cycle arrest and senescence (Crescenzi et al., 2003; Tombor et al., 2003) . Together, these data suggest that JNK may have a pivotal role in regulating cell cycle progression by modulating Bcl-2 function even though the mechanism and targets are undefined. In this report, we clearly show that Bcl-2, as a JNK target, prevents ROS generation from the mitochondria and activation of DDR. A distinctive feature of senescent cells is the elevated expression of the p16 and p21 CDK inhibitors. p16 has a key role in establishing G1 cell cycle arrest in cellular senescence (Takahashi et al., 2006) . Although p16 interacts specifically with CDK4 and CDK6, p21 interacts with multiple cyclin-CDK complexes (Oruetxebarria et al., 2004; Ruas et al., 2006) . There have been many reports of G0/G1 arrest in senescence (Kramer et al., 2001; Qian et al., 2008) . However, it was also shown that senescence was accompanied by cell cycle arrest in G2/M arrest, including SP600125-induced G2/ M arrest (MacLaren et al., 2004; Mingo-Sion et al., 2004; Wada et al., 2004; Vigneron et al., 2005; Xia et al., 2006; Oliva et al., 2008) . In this study, p21 has a major role in cell cycle arrest, and G2/M cell cycle arrest is associated with rapid CDC25 phosphorylation and decrease of cyclin B1 and CDK2 in SP600125-treated cells. Altogether, we suggest that cell cycle arrest in either G0/G1or G2/M could induce premature senescence, and this depends on the signaling pathway in each specific cellular context.
Studies have also indicated that cells undergoing senescence are more likely to be resistant to apoptosis (Zhang et al., 2006) . Bax, the first identified proapoptotic member of the Bcl-2 family, is essential for apoptotic cell death. Although Bax exists as a monomeric cytosolic protein in healthy cells, Bax undergoes a conformational change and translocates to the mitochondria where it can induce cytochrome c release and subsequent caspase activation in response to proapoptotic stimuli (Tsuruta et al., 2003; Kerr et al., 2007) . In our studies, Bax translocation to the mitochondria was not observed. Thus, cells treated with SP600125 did not induce cytochrome c release and maintained senescence without becoming apoptotic. In addition, previous reports showed that JNK activity is necessary for Bax translocation to the mitochondria (Sumayama et al., 2005; Autret et al., 2007) . As the DNA damage signaling pathway ATM/CHK2/p53 is a critical mediator of oncogene-induced senescence and apoptosis (Bartkova et al., 2006; Mallette et al., 2007) , we hypothesize that migration of Bax to the mitochondria because of the JNK activity is a critical determinant in deciding cell fate between senescence and apoptosis.
Finally, we wanted to determine whether the JNK/ Bcl-2/ROS/DNA damage signaling pathway mediates premature senescence in other carcinoma cells or primary cultured cells. We found that JNK and Bcl-2 have critical roles in preventing premature senescence, through maintenance of mitochondrial integrity, in H460 and HEF cells. Therefore, we conclude that prevention of premature senescence requires JNK regulation of Bcl-2 and ROS not only in tumor cells, but also in normal cells in primary culture.
Treatment of cancer with chemotherapeutic drugs or radiotherapy is designed to eliminate the disease by promoting apoptosis or premature senescence (Gewirtz et al., 2008) . A decrease in apoptosis can be compensated for by an increase in cells that undergo senescence. Here, we show that the combined treatment of SP600125 and IR resulted in inhibition of cell proliferation through synergistic induction of premature senescence, indicating that SP600125 could be combined with radiotherapy or other chemotherapeutic drugs in treating cancer. Our results concur with the report that showed the effectiveness of combined pharmacological interference using the JNK inhibitor with radiotherapy in treating thyroid cancer (Bulgin et al., 2006) .
To the best of our knowledge, this study is the first to report a mechanism for how the loss of JNK activity triggers premature senescence. This loss contributes to a defect in Bcl-2 phosphorylation and sequentially triggers loss of mitochondrial integrity, intracellular ROS accumulation, DDR and cell cycle arrest to lead to premature senescence. Conclusively, our results indicate that basal JNK activity is essential for maintaining cell proliferation.
Materials and methods

Reagent
Rotenone, potassium cyanide, NAC, 4 0 ,6-diamidino-2-phenylindole and taxol (paclitaxel) were obtained from the Sigma Chemical Company (St Louis, MO, USA). PD 98059, SB 203580, GÖ 6976, CGP74514A and pifithrin-a were from Calbiochem (San Diego, CA, USA), and SP600125 was from Tocris (Ellisville, MO, USA). And 2 0 ,7 0 -dichlorofluorescin diacetate was purchased from Invitrogen (Carlsbad, CA, USA).
Cell culture, antibodies and constructs Primary HEF cells, which were described in Kim et al. (2005) , were kindly supplied by Professor Jae-Yong Lee (Hallym University, Chuncheon, Korea). MCF7 and HEF cells were cultured in Dulbecco's modified Eagle's medium (HyClone, Logan, UT, USA), and H460 cells were grown in RPMI 1640 medium (HyClone) supplemented with 10% bovine growth serum (WelGENE, Daegu, Korea) and 25 U/ml penicillin/ streptomycin. The p53 antibody was purchased from Novocastra Inc. (Newcastle, UK). Phospho-pRB, phospho-JNK, phospho-Bcl-2, phospho-Cdc25C and cleaved PARP antibodies were from Cell Signaling Inc. (Danvers, MA, USA). Antibodies for the detection of JNK, p27, p21, CDK2, CDK4, cyclin A, cyclin B1, cyclin D1, cyclin E, Bcl-2, Bax and b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Catalase and a-tubulin were from Sigma-Aldrich Inc. (Oakville, Ontario, Canada). MnSOD and Cu/ZnSOD were from Stressgen Inc. (Victoria, British Columbia, Canada). Horseradish peroxidase (HRP)-conjugated goat anti-mouse was from Santa Cruz Biotechnology, and HRP-conjugated antirabbit and anti-mouse antibodies were from Amersham Inc. (Uppsala, Sweden). The wild-type, phospho-mimetic and nonphosphorylatable forms of Bcl-2 described in Deng et al. (2004) were a generous gift from Professor William S May (University of Florida, FL, USA).
Bromodeoxyuridine incorporation assay
Bromodeoxyuridine incorporation was assessed using a colorimetric enzyme-linked immunosorbent assay kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions.
Trypan blue staining A 0.4% trypan blue solution was added to the cell suspension in a 1:5 ratio, and incubated for 5 min at room temperature. Cells excluding the stain were counted by hemocytometer microscopy.
Isolation of cytosolic and mitochondrial fractions Cytosolic and mitochondrial fractions were prepared as described in Tafani et al. (2002) .
Analysis of cellular ROS levels and mitochondrial superoxide Hydrogen peroxide level was determined through 2 0 ,7 0 -dichlorofluorescin diacetate staining. Cells were incubated with 10 mM 2 0 ,7 0 -dichlorofluorescin diacetate at 37 1C for 30 min in dark and then analysed through FACScan flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA) with excitation and emission at 490 and 530 nm, respectively. For analysis of mitochondrial superoxide, MitoSOX (Invitrogen) was added to the culture media at final concentration of 10 mM. Cells were allowed to load MitoSOX for 15 min, and were washed with Hank's Buffered Salt Solution containing calcium and magnesium. Cells were trypsinized and suspended to perform flow cytometry.
Western blot analysis
For western blot analysis, we followed the protocol described in Byun et al. (2009) .
Colony formation analysis
The cells were seeded at a density of 500 cells per 60-mm dish in triplicate and cultured for 7-10 days. The colonies were fixed and stained with crystal violet (Sigma-Aldrich).
Cell cycle analysis
Cells were collected by trypsinization, fixed in 70% ethanol, washed in phosphate-buffered saline, and resuspended in 1 ml of phosphate-buffered saline containing 1 mg/ml RNase and 50 mg/ml propidium iodide. After incubation in the dark for 30 min, cell cycle distributions were analysed using EPICS flow cytometer (Beckman-Coulter Inc., Miami, FL, USA). The data were analysed using Multicycle software (Phoenix Flow Systems, San Diego, CA, USA).
Propidium iodide staining
Cells were fixed in 70% ethanol, and stained with 0.5 ml of phosphate-buffered saline containing 1 mg/ml RNase and 10 mg/ml propidium iodide for 20 min in the dark at room temperature. The data were analysed using Multicycle software (Phoenix Flow Systems).
Comet assay
It was carried out using the manufacturer's procedure of Comet Assay Kit (Cat no. 4250-00-K, Trevigen Inc. Gaithersburg, MD, USA). Olive tail moment values were calculated from at least 30 cells for each group using Kinetic Imagine software (Liverpool, UK).
Transfection
Transfection was carried out using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions.
RNA interference RNA interferences in JNK and Bcl-2 were performed using 21-bp siRNA duplexes purchased from Bioneer Inc., (Daejeon, Korea) and Cell Signaling Inc., respectively. p53 siRNA was purchased from Santa Cruz Biotechnology. Cells were transfected with 200 nM siRNA duplexes using Lipofectamine RNAiMAX according to manufacturer's protocol (Invitrogen). Nonspecific siRNA (Bioneer Inc.; AGGUA GUGUAAUCGCCUUGUU) was used as a control for comparison.
SA-b-Gal staining
We followed the protocol described in Dimri et al. (1995) .
Statistics Statistical values were expressed as mean ± s.e.m. Multiple comparisons between groups were assessed by one-way analysis of variance. Probability values o0.05 were accepted as statistically significant, and the probability values were noted as follows: P ¼ nonsignificant for >0.05; *Po0.05; **Po0.01; ***Po0.001. Data were analysed using GraphPad Prism 3.0 software (GraphPad Software, San Diego, CA, USA).
